ArticleDiabetology & metabolic syndrome2026
Global burden of cancers attributable to high fasting plasma glucose from 1990 to 2021 and projections until 2031.
Article in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThis study aims to analyze the global cancer burden attributable to high fasting plasma glucose (HFPG), and to predict disease burden trends over the next decade.
methodsThrough systematic processing and statistical analysis of data from the Global Burden of Disease Study 2021 (GBD 2021) database, we analyzed the temporal trends in HFPG-attributable cancer burden and its disparities across geographical regions, economic regions, sex, and age groups.We projected the burden for the period 2022–2031 using autoregressive integrated moving average (ARIMA) models.
resultsGlobally, the cancer burden attributable to HFPG demonstrated a consistent upward trend from 1990 to 2021. In 2021, cancer mortality attributable to HFPG reached 328,309, representing a 195% increase from the 1990 of 111,322. Within the five SDI regions, high SDI regions exhibited the greatest disease burden. Additionally, men, middle-aged, and elderly people are more severely affected. Finally, the burden of most cancers is projected to continue to rise over the next decade.
conclusionsThe study revealed a significant increasing trend in the HFPG-attributable cancer burden over the past thirty-two years. Furthermore, the cancer burden attributable to HFPG is projected to continue increasing over the next decade. It is crucial to develop targeted, tiered prevention strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.